AUS
NZ
UK
CA
USA
IND
Cyclopharm Limited (ASX:CYC) has revealed a record revenue of A$17.5 million for the first half of 2026, marking a 14% increase compared to the same period last year. The company’s US Technegas operations demonstrated remarkable growth, with revenue climbing approximately 74% year-on-year and revenue-generating primary sites doubling from 35 to 70 within six months. This expansion in the US, the world’s largest healthcare market, positions Cyclopharm as a key growth driver for the Australian nuclear imaging technology provider.
Key Highlights
- Cyclopharm Limited (CYC), an Australian healthcare tech firm, manufactures and distributes Technegas systems globally for nuclear pulmonology imaging.
- Achieved A$17.5 million revenue in 1H2026, the fifth consecutive record half-year result, reflecting 14% growth over 1H2025.
- US Technegas revenue surged approximately 74% year-on-year in 1H2026; revenue-generating sites doubled from 35 (June 2025) to 70 (June 2026), with 15 additional contracts signed in July 2026, raising contracted sites to 85.
- Operates three revenue streams: Technegas USA, Technegas Rest of World (approx. A$8.1 million), and Business Partner Product Distribution; consumables yield about 95% gross margin.
- Technegas systems are deployed in 67 countries, with direct distribution in 17, and over 5 million patient procedures completed.
- Investors should watch for updated US guidelines endorsing Technegas as the preferred ventilation imaging agent and the expansion of "Beyond PE" applications, potentially exceeding A$1 billion in opportunity.
Consistent Record-Breaking Revenue Highlights Cyclopharm’s Growth Trajectory
Cyclopharm announced its fifth consecutive record half-year revenue, reaching A$17.5 million in 1H2026, up roughly 14% from 1H2025. The company’s preliminary, unaudited results reflect a steady growth trend over two years, with revenue rising from A$12.3 million in 1H2024 to the current milestone. This sustained performance underscores the strength of Cyclopharm’s diversified product portfolio and market positioning.
The achievement of five consecutive record results highlights the maturation of Cyclopharm’s revenue diversification strategy. The Rest-of-World Technegas operations contributed about A$8.1 million in revenue, demonstrating stability across more than 65 countries. This diversified revenue base provides resilience against market fluctuations and supports the company’s expansion into new territories.
US Market Growth Fuels 74% Revenue Increase and Doubled Site Count
The US Technegas segment led Cyclopharm’s growth with a 74% year-over-year revenue increase in 1H2026. The number of revenue-generating primary sites doubled from 35 as of June 30, 2025, to 70 by June 30, 2026. The US market, the largest healthcare sector globally, has become the top revenue source for Technegas, signaling early stages of a sustained growth cycle.
Following June 2026, Cyclopharm signed 15 additional contracts in July, bringing total contracted US sites to 85. This pipeline includes expansions at institutions like University Hospital and the Department of Veterans Affairs. Approximately 52% of new installations stem from existing customers expanding within their networks, indicating strong institutional confidence and product-market fit.
Technegas’ Unique Drug-Device Model Drives High-Margin Recurring Revenue
Cyclopharm’s Technegas system combines drug, device, and service elements, including the Technegas Plus System, patient consumables, and comprehensive support services. Classified as a drug-device combination by the US FDA, this creates significant regulatory barriers for competitors and ensures product complexity that is difficult to replicate.
The company’s revenue model follows a "razor-razorblade" structure: initial system sales are followed by recurring consumable purchases, annual access fees, and engineering support. Consumables generate approximately 95% gross margins, creating a profitable, annuity-like revenue stream that compounds as the installed base grows. Specific consumables and access fee revenues were not disclosed.
Robust Global Distribution Network Spans 67 Countries
Cyclopharm maintains a global distribution network covering 67 countries, with direct distribution in 17 markets. This infrastructure has facilitated over 5 million patient procedures using Technegas. The Rest-of-World segment generated approximately A$8.1 million in revenue in 1H2026, growing 13%, reflecting mature and stable markets outside the US.
The company balances direct distribution in core markets with third-party and business partner channels, optimizing market penetration while maintaining regulatory compliance and customer relationships. This multi-channel approach supports scalable volume growth as Cyclopharm expands.
Clinical Evidence and Regulatory Endorsements Cement Technegas as Preferred Imaging Agent
Supported by over 230 PubMed publications and 2,400 Google Scholar references, Technegas is clinically validated for pulmonary embolism detection with strong sensitivity, specificity, accuracy, and negative predictive value. Updated international guidelines naming Technegas as the preferred ventilation imaging agent have received final approval, pending publication, expected to accelerate US adoption.
Technegas offers significantly lower radiation exposure (1–3 mSv) compared to computed tomography pulmonary angiography (approximately 20 mSv), benefiting patients needing repeated imaging or radiation-sensitive groups. The system supports SPECT, SPECT/CT, and planar imaging, integrating functional and anatomical data, with AI increasingly incorporated for advanced analysis.
Expanding "Beyond PE" Applications Represent Over A$1 Billion Opportunity
Cyclopharm is exploring Technegas applications beyond pulmonary embolism under a broad US FDA ventilation imaging indication. The company estimates these "Beyond PE" uses could exceed A$1 billion in market potential. Research suggests applications in chronic disease management and phenotyping patient populations not addressed by current PE imaging protocols.
Expanding indications would significantly broaden Technegas’ addressable market, potentially rivaling or surpassing current PE-focused revenues. Successful clinical validation and regulatory approval of these applications will be critical for future growth.
Elite US Hospital Adoption and Network Expansion Drive Organic Growth
Technegas adoption is strong among top-tier US healthcare institutions. Cyclopharm engages all 20 hospitals on the US News & World Report Honor Roll, with about 50% already using Technegas. Among the 100 largest US hospitals by staffed beds, 18 (18%) use Technegas; among the 200 largest, 26 (13%) are users. Approximately 85% of customers are academic or teaching centers.
Early adoption by elite institutions provides validation and encourages broader uptake across hospital networks. Around 52% of new installations are expansions within existing customer systems. While current penetration is focused on academic centers, Cyclopharm targets an addressable US market of approximately 2,000 nuclear medicine lung imaging sites, indicating significant growth potential.
Nanotechnology and AI Integration Advance Ventilation Imaging Innovation
Technegas employs nanotechnology operating at a 50-nanometre scale, enabling inert, biocompatible ventilation imaging agent deposition in the lungs. The technology has evolved from planar imaging in 1986 to advanced SPECT, SPECT/CT, and hybrid modalities.
Cyclopharm’s roadmap includes AI and machine learning to enhance imaging analysis down to subsegmental lung levels, supporting chronic disease management and identification of treatable traits. This positions Technegas at the forefront of pulmonary imaging innovation, aligning with broader healthcare analytics trends.
Mature Infrastructure and US Market Momentum Enhance Earnings Visibility
Cyclopharm’s mature global infrastructure, strong clinical evidence, and accelerating US market traction contribute to improved earnings visibility. The recurring revenue model, with high-margin consumables, strengthens cash flow as the installed base grows. The rapid doubling of US revenue-generating sites suggests potential for significant earnings contribution from this market.
Combined with steady Rest-of-World growth and business partner distribution, Cyclopharm is transitioning from a growth-stage firm to an established operator with diversified revenue streams. Investors should monitor the company’s ability to sustain 74% US revenue growth, maintain new site installation rates, and capture market share within the estimated 2,000-site US addressable market.
